Form 4: ANI Pharma Exec's Tax-Related Stock Sale

ANI Pharmaceuticals' SVP of Corporate Development and Strategy, Chad Gassert, reported a tax-related disposition of 4,269 common shares following the vesting of performance stock units.

Summary

• Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals Inc. (ANIP), reported a transaction on February 11, 2026.
• 4,269 shares of common stock were disposed of at a price of $76.25 per share.
• This disposition was for tax withholding purposes, related to the vesting of 11,578 performance stock units (PSUs) that were granted on April 6, 2023.
• Following the transaction, Chad Gassert directly owns 69,346 shares and indirectly owns 158,490 shares through Chali Properties LLC, over which he holds voting and dispositive power.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While it involves a disposition of shares, it is for tax purposes related to vested equity, indicating successful performance rather than a discretionary sale or a negative outlook.

Positives

• The transaction is a routine tax withholding event, not a discretionary sale, indicating the vesting of performance stock units.
• The vesting of 11,578 performance stock units suggests that performance targets were met, which is a positive for the company's operational achievements.

Negatives

• A reduction of 4,269 shares in direct beneficial ownership, although for tax purposes, represents a decrease in the insider's direct holdings.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports a past insider transaction.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as tax-related withholdings upon the vesting of equity awards, are common across industries and generally do not signal a change in company fundamentals or management's confidence. This type of disclosure is standard practice for executive compensation plans.

Comparison to Industry Standards

• This Form 4 filing details a standard tax-related disposition of shares upon the vesting of equity awards, which is a common practice in executive compensation across publicly traded companies.
• The structure of performance stock units and subsequent tax withholding aligns with typical corporate governance and compensation frameworks seen in companies like Pfizer, Merck, or Johnson & Johnson, where equity-based incentives are a significant component of executive pay.

Related Party Transactions

• Chad Gassert indirectly holds 158,490 shares through Chali Properties LLC, over which he holds voting and dispositive power. This is a disclosure of a related party holding, not a transaction with a related party.

Stakeholder Impact

• Shareholders: The transaction is a routine administrative event and is unlikely to have a significant direct impact on shareholders. The vesting of PSUs implies the company met certain performance criteria, which is generally positive.
• Employees: The vesting of performance stock units demonstrates the functioning of the company's performance-based compensation structure, which can be a positive signal for employee incentives.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares for tax purposes following the vesting of performance stock units. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The vesting of PSUs is a positive indicator of past performance, but the transaction itself is neutral.

Keywords

ANI Pharmaceuticals, ANIP, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Performance Stock Units, Chad Gassert, Beneficial Ownership